Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349
Kelkar SS, Prabhu VS, Corman S, Odak S, Rusibamayila N, Macahilig C, Orlowski R, Duska L. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Gynecol Oncol. 2023 Feb 1;169:154-63. doi: 10.1016/j.ygyno.2022.10.016
Haggerty A, Barrett A, Dine J, Martin L, Shah P, Buckingham T. Shared decision making in frontline maintenance therapy for ovarian cancer: a qualitative assessment. Poster presented at the 2022 Society of Gynecologic Oncology Annual Meeting; March 18, 2022. Phoenix, AZ. [abstract] Gynecol Oncol. 2022 Aug; 166(Supplement 1):S286. doi: 10.1016/S0090-8258(22)01810-8
Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.
Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.
Butler AM, Layton JB, Dharnidharka VR, McGrath LJ. Correspondence: In reply to 'High-dose versus standard-dose influenza vaccine in hemodialysis patients'. Am J Kidney Dis. 2020 Mar;75(3):456-7. doi: 10.1053/j.ajkd.2019.11.002
Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Seamans MJ, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72-83. doi: 10.1053/j.ajkd.2019.05.018.
Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018 Sep;72(3):337-48. doi: 10.1053/j.ajkd.2018.02.350.
Hallas J, Margulis AV, Pottegard A, Kristiansen NS, Atsma WJ, Appenteng K, de Vogel S, Kaye JA, Perez-Gutthann S, Arana A. Incidence of common cancers in users of antimuscarinic medications for overactive bladder: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):612-9. doi: 10.1111/bcpt.12965
Dizon D, Meyers J. The economic burden of ovarian cancer in a US managed care database. Poster presented at the 41st Annual Meeting of the Society of Gynecologic Oncologists; March 2010. [abstract] Gynecol Oncol. 2010 Mar; 116((3) Suppl 1):S121.
Foster T, Brown TM, Chang J, Menssen HD, Blieden MB, Herzog TJ. A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol. 2009 Nov 1;115:290-301.
Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.
Neubauer NL, Havrilesky LJ, Calingaert B, Bulusu A, Bernardini MQ, Fleming ND, Bland AE, Secord AA. The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol. 2009 Mar;112(3):511-6.
Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009 Jan 1;112(1):150-4.
Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.
Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008 Jan 1;51(1):62-70.
Secord AA, Havrilesky LJ, Bae-Jump V, Chin J, Calingaert B, Bland A, Rutledge TL, Berchuck A, Clarke-Pearson DL, Gehrig PA. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007 Nov 1;107(2):285-91.
Havrilesky LJ, Secord AA, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson DL, Berchuck A, Gehrig PA. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007 Jun 1;105(3):677-82.
Havrilesky LJ, Cragun JM, Calingaert B, Secord AA, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol. 2007 Feb 1;104(2):401-5.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006 Nov 1;103(2):535-40.
Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006 Jul 1;102(1):92-7.
Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005 Dec 1;99(3):689-95.
Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factorbeta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May 1;97(2):543-9.
Havrilesky LJ, Leath CA, Huh W, Calingaert B, Bentley RC, Soper JT, Secord AA. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol. 2004 May 1;93(2):429-34.
Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003 Jul 1;90(1):75-82.
Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001 Dec;83(3):466-71.